Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.6
4.9
Journals
Marine Drugs
Special Issues
Natural Products from Marine Bacteria 2024
share announcement

Natural Products from Marine Bacteria 2024

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Biotechnology Related to Drug Discovery or Production".

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 411

Special Issue Editors

Dr. Christopher Cartmell

E-Mail Website
Guest Editor
Department of Pharmacology, College of Medicine, Comprehensive Pain and Addiction Center, University of Arizona, Tucson, AZ, USA
Interests: drug discovery; marine natural products; venomics; antimicrobial resistance; targets for pain; marine biotechnology
Prof. Dr. Robert John Capon

E-Mail Website
Guest Editor
Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, Australia
Interests: biodiscovery; marine and microbial natural products chemistry; biomimetic synthesis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,                

This Special Issue of Marine drugs is titled “Natural Products from Marine Bacteria”. The aim of this Special Issue is to capture the ongoing efforts of a wide range of researchers within the marine natural product field.

The scope of the following Issue includes, but is not limited to, the following:

  • Classic marine microbial natural product discovery;
  • Marine microbial biotechnological developments for drug discovery;
  • Natural products probing marine host–symbiont interactions;
  • Marine microbial metagenomics for natural product discovery;
  • Synthesis of natural products of marine microbial origin;
  • Analogue generation of natural products of marine microbial origin.

Dr. Christopher Cartmell
Prof. Dr. Robert John Capon
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • marine bacteria
  • marine microbial natural product
  • marine microbial biotechnological
  • marine microbial
  • secondary metabolites

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

19 pages, 2859 KiB  
Article
Australian Marine and Terrestrial Streptomyces-Derived Surugamides, and Synthetic Analogs, and Their Ability to Inhibit Dirofilaria immitis (Heartworm) Motility
by Taizong Wu, Waleed M. Hussein, Kaumadi Samarasekera, Yuxuan Zhu, Zeinab G. Khalil, Shengbin Jin, David F. Bruhn, Yovany Moreno, Angela A. Salim and Robert J. Capon
Mar. Drugs 2024, 22(7), 312; https://doi.org/10.3390/md22070312 (registering DOI) - 9 Jul 2024
Abstract
A bioassay-guided chemical investigation of a bacterium, Streptomyces sp. CMB-MRB032, isolated from sheep feces collected near Bathurst, Victoria, Australia, yielded the known polyketide antimycins A4a (1) and A2a (2) as potent inhibitors of Dirofilaria immitis (heartworm) microfilaria (mf) motility [...] Read more.
A bioassay-guided chemical investigation of a bacterium, Streptomyces sp. CMB-MRB032, isolated from sheep feces collected near Bathurst, Victoria, Australia, yielded the known polyketide antimycins A4a (1) and A2a (2) as potent inhibitors of Dirofilaria immitis (heartworm) microfilaria (mf) motility (EC50 0.0013–0.0021 µg/mL), along with the octapeptide surugamide A (3) and the new N-methylated analog surugamide K (4). With biological data suggesting surugamides may also exhibit activity against D. immitis, a GNPS molecular network analysis of a library of microbes sourced from geographically diverse Australian ecosystems identified a further five taxonomically and chemically distinct surugamide producers. Scaled-up cultivation of one such producer, Streptomyces sp. CMB-M0112 isolated from a marine sediment collected at Shorncliff, Qld, Australia, yielded 3 along with the new acyl-surugamides A1–A4 (5–8). Solid-phase peptide synthesis provided additional synthetic analogs, surugamides S1–S3 (9–11), while derivatization of 3 returned the semi-synthetic surugamide S4 (12) and acyl-surugamides AS1–AS3 (13–15). The natural acyl-surugamide A3 (7) and semi-synthetic acyl-surugamide AS3 (15) were shown to selectively inhibit D. immitis mf motility (EC50 3.3–3.4 µg/mL), however, unlike antimycins 1 and 2, were inactive against the gastrointestinal nematode Haemonchus contortus L1–L3 larvae (EC50 > 25 µg/mL) and were not cytotoxic to mammalian cells (human colorectal carcinoma SW620, IC50 > 30 µg/mL). A structure–activity relationship (SAR) study on the surugamides 3–15 revealed that selective acylation of the Lys3-ε-NH2 correlates with anthelmintic activity. Full article
(This article belongs to the Special Issue Natural Products from Marine Bacteria 2024)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop